Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04064463 · ClinicalTrials.gov registry record · NA

Dual Reinforcement Contingency Management for Alcohol Use Disorders

A NA study of Alcohol Use Disorder and Contingency Management, sponsored by UConn Health.

Completed
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT04064463: Completed NA study of Alcohol Use Disorder and Contingency Management, sponsored by UConn Health.

NCT04064463 is a NA study of Alcohol Use Disorder and Contingency Management that has completed, run by UConn Health. The registered enrollment target is 74 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04064463, a NA study of Alcohol Use Disorder and Contingency Management, has completed, sponsored by UConn Health.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth results alongside attendance may increase the proportion of participants who respond to CM during and post treatment. In the proposed study, the investigators will collect PEth samples every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol use disorders. Using a two-group randomized design, participants will be assigned to standard care with PEth monitoring alone or with CM for attending treatment and submitting PEth negative samples. Compared to standard care and monitoring, the investigators expect that the CM intervention will result in greater attendance, more PEth negative samples, and higher proportions of self-reported non-drinking days, along with lower proportions of heavy drinking days, over the short term and the long term, measured throughout a 12-month follow-up. The investigators anticipate that the reinforcement intervention may decrease other drug use and sexual risk behaviors that spread HIV, reduce psychiatric symptoms, and improve quality of life as well.

Primary Outcome

longest consecutive days attended groups

Interventions

  • BEHAVIORAL Contingency management
  • BEHAVIORAL Standard care

Study Locations (1)

Connecticut

  • The Village - Hartford

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2020-01-22
Est. Completion 2025-11-25
Phase NA
UConn Health

178 total trials

What the finished NCT04064463 record still lists

NCT04064463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (77% lower).

The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Contingency management is the first listed.

NCT04064463 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT04064463 about?

NCT04064463 is a clinical study titled "Dual Reinforcement Contingency Management for Alcohol Use Disorders". Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth results alongside attendance may increase the proportion of participants who respond to CM during and post treat...

What is the current status of trial NCT04064463?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2020-01-22. Estimated completion is 2025-11-25.

What conditions does trial NCT04064463 study?

This clinical trial studies the following conditions: Alcohol Use Disorder, Contingency Management.

What interventions are being tested in trial NCT04064463?

The interventions under investigation include: Contingency management (BEHAVIORAL), Standard care (BEHAVIORAL).

Who is sponsoring clinical trial NCT04064463?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04064463 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04064463's enrollment target sits among peer trials

74 108th of 184 higher than 77 of 184 other Alcohol Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04064463, the US trial registry maintained by the National Library of Medicine. NCT04064463 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.